Overview

A Registry of Treatment Adherence for Patients With Schizophrenia

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess demographic, treatment, and outcome data in schizophrenia patients receiving treatment with long-acting injectable, tablet, or liquid formulations of first generation (conventional) or second generation (atypical) antipsychotic medications.
Details
Lead Sponsor:
Janssen-Cilag, S.A.
Treatments:
Antipsychotic Agents